exini.com

What It Is

EXINI Diagnostics AB is a Swedish medical imaging AI company founded in 1999 and originating from a research team at Lund University. It is now a wholly owned subsidiary of Lantheus Holdings, Inc. The company positions itself as a provider of trusted AI solutions for medical imaging, with products including aBSI, aPROMISE, CURE8, and PYLCLARI AI. Its main clinical focus areas include PSMA, brain imaging, and bone imaging. According to its official website, its certified solutions are used at more than 800 sites worldwide.

Core Capabilities and Use Cases

Based on the available content, EXINI’s core strength lies in AI-driven automated medical image analysis. It particularly emphasizes quantifiable and reproducible assessment of PSMA uptake and in-body distribution, supporting use cases such as precision oncology for prostate cancer, standardized PSMA scan reporting, and lesion detection and quantification in molecular imaging. Its capabilities also extend to research software and pharmaceutical services, and the company participates in the EU Thera4Care project by providing AI and data management capabilities.

Integration, Privacy, and Pricing

In terms of integration, the website states that aPROMISE is available on Siemens Healthineers’ syngo.via platform, indicating that EXINI can fit into hospital imaging workflows. However, the site does not provide an open API, SDK, deployment model, or interface documentation. For privacy, the website lists a Privacy policy and references GDPR and HIPAA, which aligns with common compliance expectations for medical AI products. That said, it does not explain data storage locations, de-identification mechanisms, or access control details. Pricing, trials, free quotas, and payment methods are not disclosed, so prospective customers will likely need to contact the sales or partnership team.

Pros and Cons

EXINI’s strengths include its long track record in medical imaging AI, clear clinical focus, broad global site footprint, and an integration case with the Siemens syngo.via platform. Its products emphasize quantification and standardization, making them suitable for institutions that need to improve consistency in image interpretation. The limitations are that the public information is mostly marketing- and product-overview-oriented, with limited disclosure of model performance metrics, regulatory certification scope, pricing, and delivery details. Chinese-language support is also not mentioned.

Who It’s For and Access from China

EXINI is better suited to hospital nuclear medicine and radiology departments, prostate cancer care teams, medical imaging research institutions, and pharmaceutical companies, rather than general-purpose AI tool users. Access from China cannot be determined from the available content; network reachability, procurement and payment, and local compliance implementation all need to be confirmed separately. If procurement is not feasible, domestic medical imaging AI alternatives that have been approved or offer stronger localization may be worth considering.